List of completed research projects from July 2008 to December

Ballmer-Hofer Kurt | OCS 02100082007 | CHF 205,700.–

Biomolekulare Forschung, Paul Scherrer Institut (PSI), Villigen

Structural and functional analysis of ligand-mediated activation of VEGF receptor 2; identification and characterization of structural motifs for the development of new receptor inhibitory drugs for anti-vascular tumor therapy

Beermann Friedrich | OCS 01500022004 | CHF 247,344.–

Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté sciences de la vie, EPF de Lausanne, Lausanne

In vivo screening of candidate genes in melanoma

Bentires-Alj Mohamed | OCS 01922082006 | CHF 275,400.–

Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel

Role of GAB2/SHP2 and 11q13 amplification in breast cancer

Brunner Thomas | OCS 02025022007 | CHF 176,900.–

Institut für Pathologie, Universität Bern, Bern

Characterization and role of extra-adrenal glucocorticoid synthesis in colorectal cancer

Christofori Gerhard | OCS 01932082006 | CHF 305,400.–

Institut für Biochemie und Genetik, Departement Biomedizin, Universität Basel, Basel

Podoplanin-mediated signalling and its role in collective cell invasion and metastasis formation

Citi Sandra | OCS 01916082006 | CHF 195,000.–

Département de biologie moléculaire, Sciences III, Université de Genève, Genève

The role of tight junction proteins in epithelial morphogenesis and differentiation

Donda Alena | OCS 02248082008 | CHF 138,300.–

Département de biochimie, Université de Lausanne, Epalinges

CD1d-anti tumor bifunctional molecules to redirect the innate and adaptive immune responses to the tumor site

Dufour Jean-François | OCS 02112082007 | CHF 209,900.–

Signal Transduction Group, Institut für klinische Pharmakologie, Universität Bern, Bern

Roles of mTORC2 and mTOC1 in hepatocellular carcinoma

Continuation in the project:

Dufour Jean-François | KFS 02541022010 | CHF 202,200.–

Institut für klinische Pharmakologie, Universität Bern, Bern

Hepatocarcinogenic roles of mTOR, raptor and rapamycins in absence of Pten

Duration: 01.08.2010 – 01.08.2013

Frei Christian | OCS 01575082004 | CHF 167,000.–

Institut für Zellbiologie, ETH Zürich, Zürich

The function of Drosophila hypoxia-inducible factor (HIF-1) and its transcriptional targets in cellular growth control

Frey-von Matt Brigitte M. | KLS 02015022007 | CHF 246,400.–

Departement für Nephrologie und Hypertonie, Inselspital, Bern

Androgen-mediated gene delivery (AMGD)

Gasser Susan | OCS 02126082007 | CHF 187,700.–

Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel

The RPA70 interaction domain of Sgs1 contributes to both replication checkpoint activation and fork stability

Gönczy Pierre | OCS 01676022005 | CHF 171,100.–

UPGON, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté sciences de la vie, EPF de Lausanne, Lausanne

Coupling cell polarity and cell division in C. elegans embryos: Novel insights into proliferation control mechanisms

Gönczy Pierre | KLS 02024022007 | CHF 335,100.–

UPGON, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne

Mechanisms of centrosome duplication in C. elegans and human cells: From model organism towards therapeutic opportunities

Grassi Fabio | OCS 01933082006 | CHF 174,300.–

Istituto di ricerca biomedica (IRB), Bellinzona

Sinergy between oncogenic Notch and pre-T cell receptor (pre-TCR) signalling microdomains in leukemogenesis

Hall Michael N. | KLS 01991022007 | CHF 350,500.–

Departement Biozentrum, Universität Basel, Basel

Proteomic analysis of the cancer-promoting mTOR pathway

Heim Markus Hermann | OCS 02192022008 | CHF 245,200.–

Klinik für Gastroenterologie und Hepatologie, Universitätsspital Basel, Basel

Hepatocarcinogenesis in chronic hepatitis C

Hemmings Brian A. | OCS 01667022005 | CHF 271,350.–

Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel

Role of protein kinase B (PKB/Akt) in cell transformation and cancer

Hemmings Brian A. | OCS 01942082006 | CHF 275,400.–

Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel

The role of human protein kinase NDR in cell morphogenesis, cell division, growth control and cancer

Herr Winship | OCS 02047022007 | CHF 301,900.–

Centre intégratif de génomique (CIG), Faculté de biologie et de médecine, Université de Lausanne, Lausanne

HCF-1 regulation of genomic stability during cell division

Hübscher Ulrich | OCS 01996022007 | CHF 251,800.–

Institut für Veterinärbiochemie und Molekularbiologie, Universität Zürich, Zürich

Repair of oxidation damages in DNA: DNA synthesis over lesions by posttranslationally modified human DNA polymerase 

Huelsken Joerg | OCS 01838022006 | CHF 336,600.–

UPHUE, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne

Role of inflammation in Wnt-mediated tumorigenesis

Hynes Nancy | KLS 02187022008 | CHF 47,600.–

Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel

Characterisation of the role of PN-1 in breast cancer and its potential as a therapeutic target

Janscak Pavel | OCS 01730082005 | CHF 221,500.–

Institut für molekulare Krebsforschung, Universität Zürich, Zürich

Study of the role of the human mismatch repair system in telomere metabolism

Krek Wilhelm | OCS 01787082005 | CHF 335,500.–

Institut für Zellbiologie, ETH Zürich, Zürich

Roles of F-box protein Skp2-based E3 ubiquitin protein ligases in cell cycle control and neoplastic signalling

Continuation in the project:

Krek Wilhelm | KFS 02690082010 | CHF 226,000.–

Institut für Zellbiologie, ETH Zürich, Zürich

Roles of the URI oncoprotein in B-RAF-signaling and melanoma cancer cell proliferation

Duration: 01.02.2011 – 01.02.2013

Lange Norbert | OCS 01948082006 | CHF 163,200.–

Laboratoire de pharmaceutique et de biopharmacie, Section des sciences pharmaceutiques, Université de Genève, Genève

Synthesis and evaluation of new water soluble polymeric photosensitizer prodrugs for photodynamic therapy

MacDonald Hugh Robson | OCS 01863022006 | CHF 346,300.–

Centre Ludwig de recherche sur le cancer, Epalinges

Moradpour Darius | OCS 01762082005 | CHF 250,700.–

Division de gastroentérologie et d’hépatologie, Centre hospitalier universitaire vaudois (CHUV), Lausanne

Development of a model system to study coinfection by hepatitis B and C viruses – the major causes of hepatocellular carcinoma

Müller Anne | OCS 02099082007 | CHF 191,500.–

Institut für molekulare Krebsforschung, Universität Zürich, Zürich

The molecular pathogenesis of Helicobacter pylori-induced mucosa-associated lymphoid tissue (MALT) lymphoma in an animal model: Analysis of the role of tumor infiltrating accessory cells in vivo and ex vivo and of the specificity of tumor immunoglobulin

Continuation in the project:

Müller Anne | KFS 02640082010 | CHF 293,700.–

Institut für molekulare Krebsforschung, Universität Zürich, Zürich

The molecular pathogenesis of Helicobacter pylori-induced mucosa-associated lymphoid tissue (MALT) lymphoma: Analysis of the role of small regulatory RNAs in lymphomagenesis and high grade transformation

Duration: 01.11.2010 – 01.11.2013

Nägeli Hanspeter | KLS 01827022006 | CHF 117,700.–

Institut für Veterinärpharmakologie und toxikologie, Universität Zürich, Zürich

Regulation of nucleotide excision repair activity by protein modifiers

Ochsenbein Adrian F. | OCS 01627022005 | CHF 274,300.–

Universitätsklinik für medizinische Onkologie, Inselspital, Bern

Immunosurveillance of chronic myeloid leukemia in mice

Orend Gertraud | OCS 01875022006 | CHF 304,100.–

Unité Inserm 682, Institut national de la santé et de la recherche médicale (INSERM), Strasbourg, France

Analysis of a potential oncogenic function of tenascin-C and tenascin-W in colon cancer

Pabst Thomas | OCS 01833022006 | CHF 249,000.–

Universitätsklinik für medizinische Onkologie, Inselspital, Bern

The myeloid key transcription factor CEBPA and the pathophysiology of acute myeloid leukemia

Pelkmans Lucas | OCS 02111082007 | CHF 198,000.–

Institut für molekulare Systembiologie, ETH Zürich, Zürich

How focal adhesion kinase (FAK) controls membrane partitioning and endocytosis of cell adhesion components in normal and in cancer cells

Peter Matthias | OCS 02189022008 | CHF 229,400.–

Institut für Biochemie, ETH Zürich, Zürich

Regulation of genome stability by Rtt101p/cullin4-based E3-ubiquitin ligases in yeast and mammalian cells

Plückthun Andreas | OCS 02128082007 | CHF 215,400.–

Biochemisches Institut, Universität Zürich, Zürich

Tumor targeting of ErbB2 with designed ankyrin repeat proteins

Pruschy Martin | OCS 02129082007 | CHF 223,100.–

Labor für molekulare Radiobiologie, Klinik für RadioOnkologie, UniversitätsSpital Zürich, Zürich

Microtubule interference as target for combined cancer therapy with ionizing radiation

Radtke Freddy | OCS 01560082004 | CHF 140,600.–

UPRAD, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne

The role of Notch2 in murine epidermis

Radtke Freddy | KLS 01840022006 | CHF 346,300.–

UPRAD, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne

The role of Notch1 signalling in acute lymphoblastic T-cell leukaemia (T-ALL)

Renner Christoph | OCS 02119082007 | CHF 192,200.–

Klinik und Poliklinik für Onkologie, Medizinbereich Innere Medizin – Onkologie, UniversitätsSpital Zürich, Zürich

Romero Pedro | OCS 02011022007 | CHF 173,600.–

Division d’oncologie clinique, Centre Ludwig de recherche sur le cancer, Lausanne

Impact of lentiviral cancer vaccines on the anti-tumor T-cell response in vivo

Rüegg Curzio | OCS 02020022007 | CHF 275,600.–

Division de pathologie expérimentale, Université de Fribourg, Fribourg

Role of integrins and Cyr61/CCN1 in tumor metastasis: Unraveling mechnisms and development of novel integrin inhibitors

Rufer Nathalie | OCS 01995022007 | CHF 204,500.–

Centre Ludwig de recherche sur le cancer, Université de Lausanne, Lausanne

Defining molecular, structural and functional T-cell receptor properties of melanoma-specific human CD8+_{T lymphocytes}

Ruiz i Altaba Ariel | OCS 01857022006 | CHF 321,900.–

Département de génétique médicale et de développement, Faculté de médecine, Université de Genève, Genève

Determination of the extent of participation of the sonic hedgehog-GLI signalling pathway in human gliomas and in their cancer stem cells

Schär Primo | OCS 02193022008 | CHF 283,400.–

Institut für Biochemie und Genetik, Departement Biomedizin, Universität Basel, Basel

The role of thymine DNA glycosylase in the maintenance of genetic and epigenetic stability and the suppression of tumorigenesis

Continuation of the project:

Schär Primo | OCS 01868022006 | CHF 210,800.–

Institut für Biochemie und Genetik, Departement Biomedizin, Universität Basel, Basel

Clarification of newly emerging roles of DNA repair in mediating the cytotoxicity of 5-fluorouracil and in the maintenance of epigenetic stability

Schübeler Dirk | KLS 01865022006 | CHF 179,500.–

Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel

Role and plasticity of DNA methylation in stem cell pluripotency and cancer

Schwaller Jürg | OCS 01830022006 | CHF 228,100.–

Forschungsgruppe Kinderleukämie, Departement Biomedizin, Universitätsspital Basel, Basel

PIM serine/threonine kinases as potential therapeutic targets in human hematological malignancies

Skoda Radek C. | OCS 01742082005 | CHF 339,000.–

Forschungsgruppe experimentelle Hämatologie, Departement Biomedizin, Universitätsspital Basel, Basel

Pathogenesis of myeloproliferative disorders

Stamenkovic Ivan | OCS 01656022005 | CHF 173,900.–

Institut universitaire de pathologie de Lausanne (IUP), Centre hospitalier universitaire vaudois (CHUV), Lausanne

Analysis of the molecular mechanisms underlying the pathogenesis of EWING’S family tumors

Suter Beat | OCS 01834022006 | CHF 243,000.–

Institut für Zellbiologie, Universität Bern, Bern

Control of the cell cycle function of Xpd and Cdk7

Tschan Mario P. | OCS 01823022006 | CHF 203,800.–

Medizinische Onkologie/Hämatologie, Departement für klinische Forschung, Universität Bern, Bern

Regulation of the DMP1-ARF-p53 tumor suppressor pathway in normal and leukemic hematopoiesis

Walker Paul R. | OCS 01754082005 | CHF 269,200.–

Centre d’oncologie, Hôpitaux universitaires de Genève (HUG), Genève

Exploration of intracerebral immune responses in a spontaneous astrocytoma model and their exploitation in novel cancer therapies

Wymann Matthias | OCS 01924082006 | CHF 293,500.–

Forschungsgruppe Krebs und Immunbiologie, Departement Biomedizin, Universität Basel, Basel

Zaugg Kathrin | OCS 02009022007 | CHF 195,500.–

Labor für angewandte RadioOnkologie, UniversitätsSpital Zürich, Zürich

Elucidating the role of the hypoxia-protective gene CPT1C in carcinogenesis

Continuation in the project:

Zaugg Kathrin | KLS 02569022010 | CHF 78,000.–

Labor für angewandte RadioOnkologie, UniversitätsSpital Zürich, Zürich

Elucidating the role of the hypoxia-protective gene CPT1C (Carnitine Palmitoyl-transferase 1C) in carcinogenesis

Duration: 01.05.2010 – 01.05.2011

Basic biomedical research

In document Cancer Research in Switzerland (Page 61-65)